Our team has recently published the first comprehensive overview of the status of health economics for medical devices and in-vitro diagnostics in China, "Health economic evaluations of medical devices in the People's Republic of China: A systematic literature review," in one of the leading European health economic journals - ClinicoEconomics and Outcomes Research.
NHS England has opened consultation on design of genetic testing service in England. The major innovation is introduction of the Genomics Centralised Laboratory Hubs.
Clinical commissioning policy determines framework for provision (target population, conditions, funding mechanisms, quality requirements) of the services in England. Current call for consultations covers bariatric surgery, PET-CT, proton beam radiotherapy, robot-assisted surgical procedures for cancer, cervical disk replacement, microprocessor-controlled knee prosthesis, deep brain stimulation for epilepsy and chronic pain, intrathecal pumps, genetic testing for BRCA1 and BRCA2 mutations, sacral nerve stimulation for urinary incontinence.
In coming months, the Italian healthcare system could face a major turning point in the reimbursement of out-patient specialist care. Italy is known as a market with quite static reimbursement system both for in- and out-patient services and no real ways to make changes in the system. Read analytical post by our Market Access Analyst, Cristina Rao, about forthcoming changes in Italian health care system.
Recently Monitor, the administrator of National Health Payment System in England, issued a report about lessons from the individual-patient level cost data collection in 2013/14. Reporting of individual patient-level data instead of collecting average unit cost data from providers will improve processes of determining tariffs and expand opportunity for benchmarking of health care providers. Validation of the cost allocation for selective procedures, including use of implants, radiography and others found problems in quality of reporting.
The outcomes from the 32 IVD’s HTAs have scattered results. In total, only six (19%) has clear positive recommendations. The remaining had either positive with restrictions, no conclusion or negative.
Conferences & Events
CEO Mattias Kyhlstedt will participate at the HTAi Meeting Global Efforts in Knowledge Transfer: HTA to Health Policy and Practice in Oslo.